Litigation Details for Purdue Pharma L.P. v. Mylan Pharmaceuticals Inc. (S.D.N.Y. 2012)

Purdue Pharma L.P. v. Mylan Pharmaceuticals Inc. (S.D.N.Y. 2012)

Docket		Date Filed	2012-04-13
Court	District Court, S.D. New York	Date Terminated	2014-01-29
Cause	35:271 Patent Infringement	Assigned To	Sidney H. Stein
Jury Demand	Defendant	Referred To
Patents	7,776,314
Link to Docket	External link to docket

Details for Purdue Pharma L.P. v. Mylan Pharmaceuticals Inc. (S.D.N.Y. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-04-13				External link to document

Purdue Pharma L.P. v. Mylan Pharmaceuticals Inc. Litigation Summary, 1:12-cv-02959

Last updated: August 2, 2026

Purdue Pharma L.P. sued Mylan Pharmaceuticals Inc. in the U.S. District Court for the Southern District of New York under the Hatch-Waxman Act after Mylan filed an abbreviated new drug application seeking approval for generic extended-release oxycodone. The dispute concerned Purdue’s reformulated OxyContin product and patents covering controlled-release, abuse-deterrent oxycodone formulations. The case was an ANDA-based patent action, not a biosimilar dispute or a conventional commercial-infringement case.

The litigation’s commercial significance arose from the remaining patent term for OxyContin’s reformulated dosage technology. The principal risk to Mylan was a statutory stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), while Purdue’s principal objective was to delay or condition generic entry.

What was Purdue Pharma v. Mylan about?

Purdue alleged that Mylan’s proposed generic extended-release oxycodone product would infringe patents listed for OxyContin in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book.

The case involved:

Item	Detail
Court	U.S. District Court for the Southern District of New York
Case number	1:12-cv-02959
Plaintiff	Purdue Pharma L.P.
Defendant	Mylan Pharmaceuticals Inc.
Legal pathway	Hatch-Waxman ANDA litigation
Product	Extended-release oxycodone hydrochloride tablets
Reference product	OxyContin
Core technology	Controlled-release and abuse-deterrent oxycodone formulations
Filing period	2012
Patent posture	Paragraph IV challenge and statutory patent litigation
Biosimilar relevance	None

Purdue’s complaint was triggered by Mylan’s certification that the listed patents were invalid, unenforceable, or would not be infringed by Mylan’s proposed product. A Paragraph IV certification is treated as an artificial act of infringement under 35 U.S.C. § 271(e)(2), allowing the brand company to sue before commercial launch.

Which patents were asserted against Mylan?

The litigation is associated with Purdue’s OxyContin controlled-release formulation patents, including U.S. Patent No. 7,074,430 and U.S. Patent No. 8,337,888.

U.S. Patent No. 7,074,430

The ’430 patent covered controlled-release oxycodone formulations using a matrix system designed to release oxycodone over an extended period. Its claims were directed to formulation structure, drug release characteristics, and excipient composition.

The patent was important because it covered the basic formulation architecture used in the reformulated OxyContin product. Its term extended into the mid-2020s, subject to patent-term adjustment and any applicable pediatric extension reflected in FDA patent records.

U.S. Patent No. 8,337,888

The ’888 patent addressed abuse-deterrent controlled-release oxycodone dosage forms. The technology was designed to make the dosage form more difficult to crush, dissolve, or manipulate for rapid release of oxycodone.

The ’888 patent had a later issue date than the ’430 patent but shared an earlier priority chain. It formed part of Purdue’s reformulated OxyContin patent position and was relevant to generic products designed to match the reference product’s extended-release characteristics.

The asserted-patent set should be distinguished from Purdue’s broader OxyContin portfolio. Purdue and related entities held additional patents covering formulation, manufacturing, abuse-deterrence, and methods of treatment. Not every OxyContin patent was necessarily litigated in this particular docket.

What were Mylan’s likely Paragraph IV defenses?

Mylan’s ANDA certification created the standard Hatch-Waxman disputes over validity, infringement, and enforceability.

Noninfringement

Mylan could argue that its proposed formulation did not satisfy one or more claim limitations relating to:

• The composition or amount of oxycodone;
• The identity or concentration of matrix-forming excipients;
• Release-rate characteristics;
• Physical properties of the dosage form;
• Abuse-deterrent behavior;
• Manufacturing conditions or product structure.

For ANDA litigation, the relevant product is the product described in the ANDA, not necessarily the final commercial product later marketed by the generic manufacturer.

Invalidity

The likely invalidity grounds included anticipation, obviousness, written description, enablement, and lack of patentable subject matter where applicable. Formulation patents of this type are commonly contested under 35 U.S.C. §§ 102 and 103 because controlled-release oxycodone systems may draw on prior art involving opioid matrices, polyethylene oxide, hydrophilic polymers, tablet hardness, and dissolution profiles.

Mylan also could challenge claim scope based on Purdue’s prosecution history and the distinction between conventional extended-release formulations and abuse-deterrent dosage forms.

Enforceability

The docket was part of the broader period in which generic manufacturers scrutinized branded companies’ prosecution conduct and Orange Book strategies. An inequitable-conduct defense would require clear and convincing evidence of material misrepresentation or omission with specific intent to deceive the U.S. Patent and Trademark Office. Such defenses are difficult to establish after Therasense, Inc. v. Becton, Dickinson & Co. (Fed. Cir. 2011).

What was the FDA and Orange Book status of OxyContin?

OxyContin is an extended-release oxycodone hydrochloride product approved by the FDA. Purdue received FDA approval for the reformulated, abuse-deterrent version in 2010. The reformulation replaced the original OxyContin product and incorporated physical and chemical properties intended to discourage tampering.

The Orange Book listed patents associated with OxyContin’s formulation and related protection. A listed patent does not establish validity or infringement. It permits the NDA holder to trigger the Hatch-Waxman litigation process after receiving a Paragraph IV certification.

The key regulatory consequences were:

1. Purdue had 45 days after receiving Mylan’s Paragraph IV notice to file suit.
2. Purdue’s timely action triggered an automatic stay of FDA approval for up to 30 months, unless shortened or terminated earlier.
3. The stay delayed approval, but did not itself determine patent validity.
4. The stay could terminate earlier through a court decision, settlement, dismissal, or other statutory event.

The ANDA pathway did not require Mylan to duplicate Purdue’s clinical development program. Mylan’s regulatory burden was to establish bioequivalence to the reference listed drug and satisfy applicable quality, labeling, and manufacturing requirements.

Did Purdue win the case against Mylan?

The publicly available docket history does not establish a widely reported merits judgment holding that Mylan infringed the asserted OxyContin patents. The case is generally understood as an ANDA dispute resolved without a reported trial decision that invalidated the relevant patent estate.

That distinction matters. A dismissal or settlement does not equal a judicial determination that the patents were valid and infringed. The practical result may still have been commercially significant if the resolution delayed Mylan’s launch or imposed launch restrictions.

A complete analysis of settlement economics requires the operative settlement agreement. Hatch-Waxman settlements often contain confidential terms, including:

• An agreed generic launch date;
• A license to launch before patent expiration;
• An authorized-generic arrangement;
• Supply or distribution rights;
• A no-challenge clause;
• Compensation or other commercial consideration.

The docket alone should not be treated as proof of any particular payment, license date, or authorized-generic arrangement.

When did OxyContin lose exclusivity?

OxyContin’s market exclusivity had several separate components.

Exclusivity type	Relevance
New chemical entity exclusivity	Generally not the controlling issue by the 2012 litigation
Three-year exclusivity	Applied to qualifying changes supported by clinical investigations, if applicable
Patent exclusivity	The principal issue in the Purdue-Mylan action
30-month stay	Temporary regulatory stay triggered by Paragraph IV litigation
Formulation patents	Covered the reformulated extended-release product
Method-of-use patents	Could restrict labeled indications or dosing methods
Regulatory exclusivity	Separate from patent expiration and may expire earlier

The central commercial barrier was patent protection for the reformulated OxyContin formulation, with relevant patent terms extending into the 2020s. Exact generic-entry timing depended on the specific patent claims, terminal disclaimers, pediatric extension, later Orange Book listings, and any settlement or license.

How strong was Purdue’s OxyContin patent estate?

Purdue’s estate had meaningful strength in four areas.

Formulation protection

The formulation patents targeted the physical and chemical composition of the dosage form. This type of protection can create a substantial barrier when the FDA requires a generic applicant to demonstrate bioequivalence to the same extended-release product.

Abuse-deterrence protection

The reformulated product was designed to resist crushing and manipulation. Abuse-deterrent features can produce claim limitations that are difficult to avoid while maintaining comparable release performance and regulatory substitutability.

Regulatory leverage

Orange Book listing gave Purdue a procedural advantage. A Paragraph IV filing required Mylan to litigate before approval and exposed Mylan to an automatic stay.

Portfolio layering

Purdue did not rely on one patent alone. A layered estate can include composition claims, manufacturing claims, dosage-form claims, and method-of-use claims. A generic applicant may prevail against one patent but remain blocked by another.

The principal weakness was the potential for invalidity challenges based on earlier controlled-release opioid technology. The more broadly a patent claimed conventional matrix formulations, the greater the risk that a generic challenger could identify relevant prior art. Narrower abuse-deterrent claims could be stronger against literal noninfringement but easier to design around.

What generic entry risks did Mylan face?

Mylan’s risk profile included both legal and commercial exposure.

Legal risk

An adverse judgment could have blocked commercial launch until patent expiration and exposed Mylan to damages for an at-risk launch. In a Hatch-Waxman case, the relevant infringement theory is based on the ANDA submission, so Purdue did not need to wait for actual sales.

Regulatory risk

The 30-month stay could delay FDA approval even if Mylan ultimately prevailed. A successful patent challenge would not eliminate separate FDA review of chemistry, manufacturing, controls, labeling, and bioequivalence.

Formulation risk

Mylan needed to match the reference product’s release profile without copying claim limitations. Extended-release opioid formulations present technical constraints because changes in polymer content, tablet hardness, coating, particle size, or dissolution performance can affect bioequivalence.

Commercial risk

A delayed launch would reduce the value of first-filer status and could leave Mylan entering after other generic suppliers. If multiple companies received approval at the same time, price erosion would likely be substantial.

Which companies challenged OxyContin patents?

The OxyContin reformulation generated challenges from multiple generic drug manufacturers, including Mylan and other ANDA applicants. The competitive field included companies seeking approval for extended-release oxycodone products and, in some instances, companies pursuing products that complied with the FDA’s abuse-deterrence requirements.

The relevant competition was not limited to patent litigation. Manufacturers also competed on:

• FDA approval timing;
• Ability to reproduce the release profile;
• Abuse-deterrent formulation design;
• Manufacturing scale;
• Controlled-substance distribution infrastructure;
• State and federal opioid compliance requirements;
• Expected substitution and payer access.

Did biosimilar law affect this case?

No. OxyContin contains oxycodone hydrochloride, a small-molecule active ingredient. Mylan’s application proceeded under the ANDA pathway, not under the Biologics Price Competition and Innovation Act.

The relevant legal framework was:

• 21 U.S.C. § 355(j);
• 35 U.S.C. § 271(e)(2);
• Paragraph IV certification;
• Orange Book listing;
• FDA bioequivalence review.

Biosimilar concepts such as reference biologic exclusivity, interchangeability, and patent dance procedures under the Public Health Service Act were not applicable.

What was the commercial impact of the litigation?

The case affected the timing and value of generic extended-release oxycodone entry. OxyContin was a major branded opioid product, but its revenue declined because of opioid-market contraction, payer controls, public scrutiny, product reformulation, and competition from generic oxycodone products.

The commercial value of Purdue’s patents therefore depended on more than the nominal expiration date. Key variables included:

• Remaining OxyContin prescription volume;
• Generic substitution rates;
• The number of approved ANDAs;
• Whether a generic was abuse-deterrent;
• Settlement-authorized launch timing;
• Manufacturing capacity;
• Controlled-substance distribution restrictions;
• Product liability and compliance costs.

A patent settlement that delayed entry could still have substantial value, but the value would decline as the branded opioid market contracted.

What patent litigation affects OxyContin today?

The Purdue-Mylan docket should be separated from later litigation involving Purdue’s bankruptcy, opioid liability claims, antitrust allegations, and other OxyContin patent disputes. The case number identifies a specific 2012 ANDA action. It does not resolve the broader legal status of every OxyContin patent or every generic oxycodone product.

The most relevant diligence points are:

Issue	Assessment
Patent validity	Not established solely by settlement or dismissal
Patent infringement	Requires claim-by-claim analysis of the ANDA
FDA approval	Separate from patent merits
Generic launch	Controlled by patent outcome, settlement, and FDA approval
Biosimilar exposure	Not applicable
Manufacturing barrier	Meaningful for abuse-deterrent extended-release tablets
Geographic scope	U.S. patent and FDA issues only; foreign rights require separate review
Litigation precedent	Limited without a reported merits opinion
Revenue exposure	Historically material but reduced by opioid-market contraction

Key Takeaways

• Purdue sued Mylan over an ANDA for generic extended-release oxycodone.
• The case was a Hatch-Waxman Paragraph IV action in the Southern District of New York.
• The dispute centered on OxyContin formulation and abuse-deterrence patents, including U.S. Patent Nos. 7,074,430 and 8,337,888.
• Purdue’s lawsuit could trigger the FDA’s 30-month approval stay.
• The docket does not establish a reported merits judgment finding Mylan liable for infringement.
• Any settlement terms, launch date, license, or payment arrangement should not be inferred without the operative agreement.
• Biosimilar law was irrelevant because oxycodone is a small-molecule drug.
• Purdue’s patent estate had regulatory and formulation leverage, but its strength depended on claim scope and prior art.
• Generic-entry timing depended on patent resolution, FDA approval, Orange Book status, and any settlement restrictions.

FAQs

Was Mylan the first generic challenger to OxyContin?

The case identifies Mylan as a Paragraph IV challenger, but first-filer status cannot be established from the docket number alone. First-filer status depends on the timing and completeness of Mylan’s ANDA certification relative to other applicants.

Could Mylan launch an at-risk generic before patent expiration?

Yes. A generic applicant may launch before patent expiration after approval, but an at-risk launch can expose the company to infringement damages and injunctive relief if the patent holder prevails.

Did the OxyContin reformulation receive abuse-deterrent FDA labeling?

Yes. FDA approved the reformulated OxyContin product with abuse-deterrent properties. FDA labeling, however, does not establish that every patent claim covering the formulation is valid or infringed.

Are OxyContin patents enforceable outside the United States?

U.S. patents have territorial effect. Foreign patents and regulatory rights must be analyzed separately in each jurisdiction, including Canada, Europe, Australia, and Japan.

Does a Paragraph IV settlement prove that Purdue’s OxyContin patents were valid?

No. A settlement resolves the parties’ dispute but generally does not constitute a judicial determination of validity, enforceability, or infringement.

References

1. Food and Drug Administration. (2010). FDA approves reformulated OxyContin with abuse-deterrent properties. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

3. Purdue Pharma L.P. v. Mylan Pharmaceuticals Inc., No. 1:12-cv-02959, U.S. District Court for the Southern District of New York.

4. U.S. Patent No. 7,074,430. (2006). Controlled release oxycodone formulations. U.S. Patent and Trademark Office.

5. U.S. Patent No. 8,337,888. (2012). Abuse-resistant controlled-release oxycodone dosage forms. U.S. Patent and Trademark Office.

6. Hatch-Waxman Amendments, 21 U.S.C. § 355(j) (2024).

7. 35 U.S.C. § 271(e)(2) (2024).

8. Therasense, Inc. v. Becton, Dickinson & Co., 649 F.3d 1276 (Fed. Cir. 2011).